Binding Promiscuity of Therapeutic Factor VIII
Thrombosis and Haemostasis · 01.03.2025 · 125 (03) · 194-206
DOI: 10.1055/a-2358-0853 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.03.2025. Verfasst von Alejandra Reyes Ruiz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale, CNRS, Sorbonne Université, Université Paris Cité, Pari…. Hauptthemen laut MEDLINE: Factor VIII, Hemophilia A. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 147 Literaturangaben. Gefördert von: Indo-French Centre for the Promotion of Advanced Research, European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie, Fondation pour la Recherche Médicale.
Abstract (Originalsprache)
The binding promiscuity of proteins defines their ability to indiscriminately bind multiple unrelated molecules. Binding promiscuity is implicated, at least in part, in the off-target reactivity, nonspecific biodistribution, immunogenicity, and/or short half-life of potentially efficacious protein drugs, thus affecting their clinical use. In this review, we discuss the current evidence for the binding promiscuity of factor VIII (FVIII), a protein used for the treatment of hemophilia A, which displays poor pharmacokinetics, and elevated immunogenicity. We summarize the different canonical and noncanonical interactions that FVIII may establish in the circulation and that could be responsible for its therapeutic liabilities. We also provide information suggesting that the FVIII light chain, and especially its C1 and C2 domains, could play an important role in the binding promiscuity. We believe that the knowledge accumulated over years of FVIII usage could be exploited for the development of strategies to predict protein binding promiscuity and therefore anticipate drug efficacy and toxicity. This would open a mutational space to reduce the binding promiscuity of emerging protein drugs while conserving their therapeutic potency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale, CNRS, Sorbonne Université, Université Paris Cité, Paris, France.
- Centre for Bio-Separation Technology (CBST), Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, India.
Förderung
- Indo-French Centre for the Promotion of Advanced Research
- European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie
- Fondation pour la Recherche Médicale
Zitieren
APA
Reyes Ruiz, A., Bhale, A. S., Venkataraman, K., Dimitrov, J. D., & Lacroix-Desmazes, S. (2025). Binding Promiscuity of Therapeutic Factor VIII. Thrombosis and Haemostasis, 125(03), 194-206. https://doi.org/10.1055/a-2358-0853
Vancouver
Reyes Ruiz A, Bhale AS, Venkataraman K, Dimitrov JD, Lacroix-Desmazes S. Binding Promiscuity of Therapeutic Factor VIII. Thrombosis and Haemostasis. 2025;125(03):194-206. doi:10.1055/a-2358-0853
BibTeX
@article{ReyesRuiz2025,
author = {Reyes Ruiz, Alejandra and Bhale, Aishwarya S and Venkataraman, Krishnan and Dimitrov, Jordan D and Lacroix-Desmazes, Sébastien},
title = {Binding Promiscuity of Therapeutic Factor VIII},
journal = {Thrombosis and Haemostasis},
year = {2025},
volume = {125},
number = {03},
pages = {194--206},
doi = {10.1055/a-2358-0853}
}
EUVIMED